<code id='519397B4CB'></code><style id='519397B4CB'></style>
    • <acronym id='519397B4CB'></acronym>
      <center id='519397B4CB'><center id='519397B4CB'><tfoot id='519397B4CB'></tfoot></center><abbr id='519397B4CB'><dir id='519397B4CB'><tfoot id='519397B4CB'></tfoot><noframes id='519397B4CB'>

    • <optgroup id='519397B4CB'><strike id='519397B4CB'><sup id='519397B4CB'></sup></strike><code id='519397B4CB'></code></optgroup>
        1. <b id='519397B4CB'><label id='519397B4CB'><select id='519397B4CB'><dt id='519397B4CB'><span id='519397B4CB'></span></dt></select></label></b><u id='519397B4CB'></u>
          <i id='519397B4CB'><strike id='519397B4CB'><tt id='519397B4CB'><pre id='519397B4CB'></pre></tt></strike></i>

          Home / Wikipedia / knowledge

          knowledge


          knowledge

          author:entertainment    Page View:9839

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In